Long-term effects of netakimab on health-related quality of life, back pain and work productivity in patients with ankylosing spondylitis: results of the international, multicentre, randomized double-blind phase III clinical trial BCD-085-5/ASTERA

Author:

Dubinina T. V.1ORCID,Demina A. B.1ORCID,Agafonova E. M.1ORCID,Erdes Sh. F.1ORCID,Mazurov V. I.2ORCID,Gaydukova I. Z.3ORCID,Pristrom A. M.4ORCID,Kunder E. V.4ORCID,Soroka N. F.5ORCID,Kastanayan A. A.6ORCID,Povarova T. V.7ORCID,Zhugrova E. S.8ORCID,Plaksina T. V.9ORCID,Shesternya P. A.10ORCID,Kropotina T. V.11ORCID,Antipova O. V.12ORCID,Smolyarchuk E. A.13ORCID,Tsyupa O. A.14ORCID,Abdulganieva D. I.15ORCID,Lapshina S. A.15ORCID,Krechikova D. G.16ORCID,Gordeev I. G.17ORCID,Nesmeyanova O. B.18ORCID,Tyrenko V. V.19ORCID,Ilivanova E. P.20ORCID,Strelkova A. V.21ORCID

Affiliation:

1. V.A. Nasonova Research Institute of Rheumatology

2. I.I. Mechnikov North-Western State Medical University, Ministry of Health of Russia

3. I.I. Mechnikov North-Western State Medical University, Ministry of Health of Russia; Clinical Rheumatology Hospital Twenty-Five

4. First City Clinical Hospital

5. Belarusian State Medical University

6. Rostov State Medical University, Ministry of Health of Russia

7. RhD-Meditsina Clinical Hospital of the City of Saratov

8. I.I. Mechnikov North-Western State Medical University, Ministry of Health of Russia; City Polyclinic Thirty-Eight

9. N.A. Semashko Nizhny Novgorod Regional Clinical Hospital

10. Professor V.F. Voino-Yasenetsky Krasnoyarsk State Medical University, Ministry of Health of Russia

11. Regional Clinical Hospital

12. Irkutsk City Clinical Hospital One

13. I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)

14. City Hospital Four of the City of Barnaul

15. Kazan State Medical University, Ministry of Health of Russia

16. RhD-Meditsina Clinical Hospital of the City of Smolensk

17. O.M. Filatov City Clinical Hospital Fifteen, Moscow Healthcare Department

18. Chelyabinsk Regional Clinical Hospital

19. Military medical academy named after S.M. Kirov

20. Leningrad Regional Clinical Hospital

21. E.E. Volosevich First City Clinical Hospital

Abstract

The article contains the data obtained during the 156-week follow-up of patients with ankylosing spondylitis (AS) in the ASTERA phase III study.Objective: to evaluate the effect impact of netakimab (NTK) on quality of life (QoL), back pain and work capacity in patients with active AS.Material and methods. The study enrolled 228 patients with active AS who were randomized 1:1 to receive NTK 120 mg or placebo. At week 52, patients in Group 1 (NTK) who achieved ASAS20 continued therapy (NTK at a dose of 120 mg once every 2 weeks) until week 156. Patients in Group 2 (placebo/NTK) received the study drug at a dose of 120 mg subcutaneously every 2 weeks from week 20 until week 68, after which the efficacy of therapy was determined (by achieving an ASAS20 response). Patients who achieved ASAS20 received treatment (NTK at a dose of 120 mg once every 2 weeks) until week 172.Results and discussion. Under NTK therapy, a significant improvement in QoL was observed in the assessment of the physical and psychological components of the SF-36 questionnaire, which was maintained during the three years of therapy: increase in indicator by 12.68±9.92; 13.27±10.14; 12.92±10.03; 14.10±10.35; 14.76±9.77 and 6.10±11.59; 5.50±11.82; 6.32±11.01; 5.87±11.45; 5.25±11.98 points at week 52, 76, 104, 128 and 156, respectively. During the extended therapy period, a reduction in the proportion of working hours missed for health reasons, an improvement in work capacity and work efficiency and an increase in daily activity were observed. Back pain (BASDAI question 2) and nocturnal back pain decreased steadily during the entire follow-up period compared to the screening values.Conclusion. NTK is an effective therapy for active AS that improves QoL scores, significantly reduces pain intensity and improves work productivity.

Publisher

IMA Press, LLC

Subject

Pharmacology (medical),Immunology,Immunology and Allergy,Rheumatology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3